LOGIN  |  REGISTER
Cue Biopharma

Waystar to Participate in Upcoming Investor Conferences

November 18, 2025 | Last Trade: US$36.18 0.86 -2.32

LEHI, Utah and LOUISVILLE, Ky., Nov. 18, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins and Chief Financial Officer Steve Oreskovich will participate in three upcoming investor conferences:

  • 8th Annual Evercore ISI HealthCONx Conference: Mr. Oreskovich will conduct one-on-one meetings on Tuesday, December 2, 2025.
  • Citi's 2025 Global Healthcare Conference: Mr. Oreskovich will participate in a fireside chat on Wednesday, December 3, 2025, at 1:45 p.m. ET and conduct one-on-one meetings.
  • Barclays 23rd Annual Global Technology Conference: Mr. Hawkins will participate in a fireside chat on Wednesday, December 10, 2025, at 3:40 p.m. PT and conduct one-on-one meetings.

Waystar will provide live webcasts of the Citi and Barclays fireside chats on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 17 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward atwaystar.com.

Media Contact 
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
Sue Dooley
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page